CMS Measure ID:
Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater (indicated by HCPCS code) and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.
Initial Patient Population:
Male patients with a diagnosis of prostate cancer and an order for ADT that is intended for greater than or equal to12 months during the measurement period. Also included are male patients with a diagnosis of prostate cancer with ADT that was administered with an intent of 12 months or greater therapy and began during the measurement period.
Equals Initial Population
Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment
Patient refused recommendation for a bone density evaluation after the start of ADT therapy
Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy Print
Modified on: Mon, 8 Apr, 2019 at 11:28 AM
Did you find it helpful?Send feedback
Sorry we couldn't be helpful. Help us improve this article with your feedback.